Company News

Share this article:

Pfizer and Bausch & Lomb announced a co-promotion deal for both companies' prescription ophthalmic pharmaceuticals in the US. The five year agreement includes Pfizer's Xalatan, and Bausch & Lomb's Alrex, Lotemax, Zylet, and the company's investigational anti-infective eye drop, besifloxacin ophthalmic suspension (0.6%), which is currently under FDA review.

Pfizer has entered into agreements with Aurobindo Pharma, an India-based pharmaceutical company, to commercialize generic medications in the US and Europe. The move progresses the company's established products business unit, which is focused on the commercialization of products where market exclusivity has been lost.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.